

**Amendments to the Claims:**


Please amend claim 22 and add claim 42, as shown in the listing of claims that follows.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-13 (canceled).

14. (Previously presented) A pharmaceutical composition adapted for oral administration, comprising a pharmaceutically acceptable carrier and from one milligram to four hundred milligrams of a biologically active agent, wherein the agent is a compound of the formula:



Formula I

wherein

n is 1 or 2;

m is 0, 1, 2, 4, or 5;

q is 0 or 1;

t is 0 or 1;

R<sup>2</sup> is alkyl having from 1 to 3 carbon atoms;

R<sup>3</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl;

and

R<sup>1</sup> is hydrogen or alkyl having 1 or 2 carbon atoms;

or when R<sup>1</sup> is hydrogen, a pharmaceutically acceptable salt of the compound.

15. (Previously presented) The pharmaceutical composition of claim 14, wherein n is 1; q is 0; t is 0; R<sup>3</sup> is hydrogen; and A is phenyl, substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy.


16. (Original) The pharmaceutical composition of claim 15, wherein A is 2,6-dimethylphenyl.

17. (Previously presented) The pharmaceutical composition of claim 16, wherein the biologically active agent is selected from the group consisting of: 3-(2,6-Dimethylbenzyloxy)phenylacetic acid;

3-(2,6-Dimethylbenzyloxy)benzoic acid;  
Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;  
6-[3-(2,6-Dimethylbenzyloxy)-phenyl]-hexanoic acid;  
Ethyl 6-[3-(2,6-dimethylbenzyloxy)-phenyl]-hexanoate;  
5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pentanoic acid;  
Ethyl 5-[3-(2,6-dimethylbenzyloxy)-phenyl]-pentanoate;  
3-[3-(2,6-dimethylbenzyloxy)phenyl]-propionic acid; and  
Ethyl 3-[3-(2,6-dimethylbenzyloxy)phenyl]-propanoate.

18. (Previously presented) The pharmaceutical composition of claim 14 in oral dosage form.

19. (Previously presented) A biologically active agent, wherein the agent is a compound of the formula:



Formula I

wherein

n is 1 or 2;

m is 1, 2, 4, or 5;

q is 0 or 1;

t is 0 or 1;

R<sup>2</sup> is alkyl having from 1 to 3 carbon atoms;

R<sup>3</sup> is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is 2,6-dimethylphenyl ; and

R<sup>1</sup> is hydrogen or alkyl having 1 or 2 carbon atoms;

or when R<sup>1</sup> is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is substantially pure.

20. (Canceled)

21. (Canceled)

22. (Currently amended) The biologically active agent of claim 19, selected from the group consisting of:

3-(2,6-Dimethylbenzyloxy)phenylacetic acid;

~~3-(2,6-Dimethylbenzyloxy)benzoic acid;~~

~~Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;~~

6-[3-(2,6-Dimethylbenzyloxy)-phenyl]-hexanoic acid;

Ethyl 6-[3-(2,6-dimethylbenzyloxy)-phenyl]-hexanoate;

5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pentanoic acid;

Ethyl 5-[3-(2,6-dimethylbenzyloxy)-phenyl]-pentanoate;

3-[3-(2,6-dimethylbenzyloxy)phenyl]-propionic acid; and

Ethyl 3-[3-(2,6-dimethylbenzyloxy)phenyl]-propanoate.


Claim 23 (canceled).

Claim 24 (canceled).

25. (Previously presented) The pharmaceutical composition of claim 17, wherein the biologically active agent is 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.

26. (Previously presented) The biologically active agent of claim 22, being 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.

27. (Previously presented) A biologically active agent, wherein the agent is a compound of the formula:



Formula I

wherein

n is 1 or 2;

m is 0, 1, 2, 4, or 5;

q is 0 or 1;

t is 0 or 1;

$R^2$  is alkyl having from 1 to 3 carbon atoms;

$R^3$  is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;

A is phenyl, substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy;

and

$R^1$  is hydrogen or alkyl having 1 or 2 carbon atoms;

or when  $R^1$  is hydrogen, a pharmaceutically acceptable salt of the compound, wherein the agent is present in a mammal other than a mouse.

28. (Previously presented) The biologically active agent of claim 27, wherein n is 1; q is 0; t is 0; and  $R^3$  is hydrogen

29. (Previously presented) The biologically active agent of claim 28, wherein A is 2,6-dimethylphenyl.

30. (Previously presented) The biologically active agent of claim 29, selected from the group consisting of:

3-(2,6-Dimethylbenzyloxy)phenylacetic acid;

3-(2,6-Dimethylbenzyloxy)benzoic acid;

Ethyl 3-(2,6-dimethylbenzyloxy)benzoate;

6-[3-(2,6-Dimethylbenzyloxy)-phenyl]-hexanoic acid;

Ethyl 6-[3-(2,6-dimethylbenzyloxy)-phenyl]-hexanoate;

5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pentanoic acid;

Ethyl 5-[3-(2,6-dimethylbenzyloxy)-phenyl]-pentanoate;

3-[3-(2,6-dimethylbenzyloxy)phenyl]-propionic acid; and

Ethyl 3-[3-(2,6-dimethylbenzyloxy)phenyl]-propanoate.

31. (Previously presented) The biologically active agent of claim 30, being 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid.

32. (Previously presented) The biologically active agent of claim 31, wherein the mammal is a human.

33. (Previously presented) The biologically active agent of claim 27, wherein the mammal is a human.

Claims 34-41 (canceled).

42. (New) A biologically active agent selected from the group consisting of 3-(2,6-Dimethylbenzyloxy)benzoic acid, pharmaceutically acceptable salts thereof, and Ethyl 3-(2,6-dimethylbenzyloxy)benzoate, wherein the agent is substantially pure.